Loading…

More Than Three-Fourths of AstraZeneca

Background: Ethiopia was using the ChAdOx1 COV-19 vaccine, and health professionals were targets of the first phase of the vaccination strategy. Evidence on the adverse events following immunization (AEFI) was barely available. The study aimed to assess the magnitude and associated factors of advers...

Full description

Saved in:
Bibliographic Details
Published in:Infection and drug resistance 2022-05, Vol.15, p.2409
Main Authors: Muluneh, Atalay Goshu, Tilahun, Sewbesew Yitayih, Yimer, Mulugeta Ayalew, Abereha, Aklilu Yiheyis, Gelaye, Kassahun Alemu, Sugamo, Kalkidan Samuel, Merid, Mehari Woldemariam, Kassa, Getahun Molla, Teshager, Nahom Worku
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Ethiopia was using the ChAdOx1 COV-19 vaccine, and health professionals were targets of the first phase of the vaccination strategy. Evidence on the adverse events following immunization (AEFI) was barely available. The study aimed to assess the magnitude and associated factors of adverse events following ChAdOx1 COV-19 immunization among health professionals of the University of Gondar Specialized and Comprehensive Hospital, 2021. Methods: An institution-based cross-sectional study was conducted among health professionals of the University of Gondar Comprehensive and specialized referral hospital. All health professionals who took the ChAdOx1 COV-19 vaccine in the 1st phase were surveyed. A total of 314 health professionals who took the ChAdOx1 COV-19 vaccine were included. The EpiData version 4.6.0.0 and Stata 16 were used for data entry and analysis, respectively. A binary logistic regression was used to identify statistically significant factors associated with AEFI. Chi-square and multicollinearity assumptions were tested. A p-value
ISSN:1178-6973
1178-6973